Farnesyltransferase (FTase) inhibitors (FTIs) block a lipid modification critical for Ras membrane association and biological function, and easily inhibit H-Ras transforming activity in vitro and in animal models. Therefore, FTIs are under intense investigation as highly promising potential anti-cancer therapeutic agents. However, recent developments have made clear that the mechanism of FTI action is unexpectedly complex and not understood, although it certainly includes, although it certainly includes inhibition of FTase. Among the complexities are the findings that the excellent and straightforward results with H-Ras cannot be extrapolated to K-Ras; that K-Ras, the most commonly mutated form of Ras in human tumors, is highly resistant to FTI action; that FTI inhibition of transformation can be unlinked from inhibition of K-ras processing; and that Ras mutation status is not predictive for FTI sensitivity. There is general agreement that a likely explanation for some of these findings is the existence of critically important but as yet unidentified non-Ras targets of FTI action. However, both the academic and the pharmaceutic research communities are deeply divided over the significance and possible explanations for (and, therefore, of methods to overcome) the unexpectedly high resistance of K-Ras to FTIs. The existence and nature of this resistance has important implication, both for our understanding of the role and mechanism of action of the two different farnesylated Ras proteins in cellular transformation and for future successful drug design. The overall goals of this proposal are, therefore, to determine the basis for K-Ras resistance to FTI action and to determine the mechanism of FTI inhibition of transformation. To accomplish these goals, we propose to determine the relative contributions to FTI resistance of the high affinity of K-Ras for FTase and of possible alternative prenylation of K- Ras in human tumor cells; to compare the relative ability of unprocessed forms of H-, N-, and K-Ras to act as dominant negatives to block oncogenic Ras transformation; and to identify other physiologically important farnesylated targets for FTIs. The results of these experiments will provide further insight into the unexpectedly complex mechanisms of Ras processing and transformation and will provide fruitful directions for improvement in FTIs, as well as novel targets for drug design.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA076092-03
Application #
6137628
Study Section
Pathology B Study Section (PTHB)
Program Officer
Forry-Schaudies, Suzanne L
Project Start
1998-01-01
Project End
2000-12-31
Budget Start
2000-01-31
Budget End
2000-12-31
Support Year
3
Fiscal Year
2000
Total Cost
$170,110
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Grana, Theresa M; Sartor, Carolyn I; Cox, Adrienne D (2003) Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res 63:7807-14
Grana, Theresa M; Rusyn, Elena V; Zhou, Hong et al. (2002) Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 62:4142-50
Hansen, Malene; Rusyn, Elena V; Hughes, Paul E et al. (2002) R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras. Oncogene 21:4448-61
Chiu, Vi K; Bivona, Trever; Hach, Angela et al. (2002) Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 4:343-50
Fiordalisi, James J; Holly, Stephen P; Johnson 2nd, Ronald L et al. (2002) A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion. J Biol Chem 277:10813-23
Alton, G; Cox, A D; Toussaint 3rd, L G et al. (2001) Functional proteomics analysis of GTPase signaling networks. Methods Enzymol 332:300-16
Cox, A D (2001) Farnesyltransferase inhibitors: potential role in the treatment of cancer. Drugs 61:723-32
Fiordalisi, J J; Johnson 2nd, R L; Ulku, A S et al. (2001) Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. Methods Enzymol 332:3-36
Sherman, L S; Atit, R; Rosenbaum, T et al. (2000) Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J Biol Chem 275:30740-5